<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes of cholestasis in neonates and young infants</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes of cholestasis in neonates and young infants</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes of cholestasis in neonates and young infants</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Wehrman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathleen M Loomes, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven A Abrams, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth B Rand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neonatal cholestasis is generally defined as conjugated hyperbilirubinemia that occurs in the newborn period or shortly thereafter (ie, within the first three months of life). Cholestasis results from diminished bile formation and/or excretion, which can be caused by a number of disorders, most commonly biliary atresia.</p><p>The most common causes of neonatal cholestasis will be reviewed here. Details about biliary atresia and the approach to infants with neonatal cholestasis, including differentiation between extrahepatic obstruction and intrahepatic disease, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5941.html" rel="external">"Approach to evaluation of cholestasis in neonates and young infants"</a>.)</p><p class="headingAnchor" id="H2010406277"><span class="h1">DEFINITION AND CLASSIFICATION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholestasis</strong> – Cholestasis is defined as an impairment in the excretion of bile, which can be caused by defects in intrahepatic production of bile, transmembrane transport of bile, or mechanical obstruction to bile flow. The biochemical features of cholestasis reflect the retention of components of bile in the serum (eg, bilirubin, bile acids, and/or cholesterol). The pattern and severity of each of these abnormalities vary with the underlying disorder. Elevated conjugated bilirubin is the predominant characteristic in most of the causes of neonatal cholestasis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal cholestasis</strong> – The term "neonatal cholestasis" is often used to refer to cholestatic liver disease that is present at birth and/or develops within the first few months of life, rather than referring strictly to the neonatal period (the first 28 days of life).</p><p></p><p>Causes of neonatal cholestasis can be divided into the following categories  (<a class="graphic graphic_table graphicRef64995 graphicRef79511" href="/z/d/graphic/64995.html" rel="external">table 1A-B</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive (eg, biliary atresia)</p><p class="bulletIndent1"><span class="glyph">●</span>Infectious (eg, congenital cytomegalovirus)</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic/metabolic (eg, Alagille syndrome, progressive familial intrahepatic cholestasis [PFIC], and several inborn errors of metabolism)</p><p class="bulletIndent1"><span class="glyph">●</span>Alloimmune (eg, gestational alloimmune liver disease [GALD])</p><p class="bulletIndent1"><span class="glyph">●</span>Toxic (eg, intestinal failure-associated liver disease [IFALD], related to parenteral nutrition)</p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic (idiopathic neonatal hepatitis)</p><p></p><p>In clinical practice, these disorders usually become apparent within the first two months of life, which is the critical period for identifying infants with biliary atresia, the most common cause of cholestasis in this age group. Biliary atresia must be differentiated from other causes of cholestasis promptly because early surgical intervention (ie, before two months of age) results in a better patient outcome. Furthermore, other treatable disorders require prompt diagnosis to initiate effective therapy (eg, tyrosinemia, galactosemia, hypothyroidism, and infectious causes).</p><p class="headingAnchor" id="H4172188326"><span class="h1">OBSTRUCTIVE CAUSES</span></p><p class="headingAnchor" id="H2"><span class="h2">Biliary atresia</span><span class="headingEndMark"> — </span>Biliary atresia is a progressive idiopathic disease of the extrahepatic biliary tree that presents with clinical signs of biliary obstruction in young infants. Biliary atresia is the most common cause of conjugated hyperbilirubinemia in young infants in resource-abundant countries, accounting for approximately 20 to 30 percent of cases [<a href="#rid1">1</a>]. Infants with biliary atresia tend to be healthy at birth and develop progressive jaundice within the first eight weeks of life, often with acholic (pale-colored) stools. Studies have shown that infants later diagnosed with biliary atresia have mildly abnormal direct or conjugated bilirubin in the first days of life, presenting an opportunity for newborn screening [<a href="#rid2">2</a>].</p><p>Biliary atresia must be recognized promptly because early surgical intervention (eg, before 60 days of age) substantially improves outcome [<a href="#rid3">3</a>]. It is distinguished from other causes of neonatal cholestasis by a variety of tests, and the diagnosis is confirmed by intraoperative cholangiogram. Even when optimally managed, a majority of individuals with biliary atresia ultimately require liver transplantation.</p><p>The pathogenesis, clinical features, diagnosis, and treatment of biliary atresia are discussed in detail in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Biliary cysts</span><span class="headingEndMark"> — </span>Biliary cysts are a rare but treatable cause of conjugated hyperbilirubinemia. They were originally termed choledochal cysts because they usually involve the extrahepatic bile duct. Five anatomic variants have been described  (<a class="graphic graphic_figure graphicRef80937" href="/z/d/graphic/80937.html" rel="external">figure 1</a>), but most affected infants have diffuse enlargement of the common bile duct (type 1, representing 50 to 80 percent of biliary cysts [<a href="#rid4">4</a>]) [<a href="#rid5">5,6</a>]. In addition to jaundice, affected infants may have abdominal pain, an abdominal mass, and vomiting. Some infants in whom biliary cysts are diagnosed by prenatal ultrasound are asymptomatic during the neonatal period.</p><p>The cyst usually can be detected by ultrasonography and should be further evaluated by magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), and/or intraoperative cholangiopancreatography [<a href="#rid7">7</a>]. Biliary cysts must be differentiated from cystic biliary atresia. In infants with biliary cysts, the intrahepatic bile ducts are normal or dilated rather than sclerosed. Ultrasonographic findings suggestive of biliary cysts rather than biliary atresia include larger cyst size, dilated intrahepatic bile ducts, and normal-appearing gallbladder [<a href="#rid8">8</a>].</p><p>Management depends on the type of cyst and presence of biliary obstruction, but most cases presenting during the neonatal period will require surgical resection rather than the Kasai procedure used for patients with biliary atresia. Removal of the cyst can prevent the development of ascending cholangitis or biliary adenocarcinoma [<a href="#rid5">5</a>]. A randomized trial showed that fibrotic liver disease is likely to develop even in asymptomatic infants and that early surgical intervention (≤1 month of age) is beneficial compared with late (≥1 month of age) intervention [<a href="#rid9">9</a>].</p><p>Prognosis is better for patients with biliary cysts than those with biliary atresia [<a href="#rid10">10</a>]. However, patients with biliary cysts may be at risk for later development of cholangiocarcinoma even after resection and should be monitored periodically with imaging and blood work. (See  <a class="medical medical_review" href="/z/d/html/5867.html" rel="external">"Endoscopic retrograde cholangiopancreatography (ERCP) for biliary disease in children", section on 'Biliary cysts'</a> and  <a class="medical medical_review" href="/z/d/html/651.html" rel="external">"Biliary cysts"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Other obstructive causes</span><span class="headingEndMark"> — </span>Other extrahepatic causes of biliary obstruction in young infants include:</p><p class="bulletIndent1"><span class="glyph">●</span>Inspissated bile/plug syndrome (eg, patients with cystic fibrosis [CF])</p><p class="bulletIndent1"><span class="glyph">●</span>Gallstones or biliary sludge</p><p class="bulletIndent1"><span class="glyph">●</span>Tumors</p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal sclerosing cholangitis</p><p></p><p class="headingAnchor" id="H10"><span class="h1">INFECTIOUS CAUSES</span><span class="headingEndMark"> — </span>Bacterial, protozoal, and viral infections can result in cholestasis. The proportion of cholestasis attributed to infection varies markedly across studies, likely depending on the population [<a href="#rid1">1</a>]. Common congenitally acquired pathogens include cytomegalovirus, toxoplasmosis, rubella, herpes, and syphilis. Less frequent causes are echovirus, adenovirus, and parvovirus B19. (See  <a class="medical medical_review" href="/z/d/html/6011.html" rel="external">"Overview of TORCH infections"</a>.)</p><p>Bacterial infections with gram-positive and gram-negative organisms also have been associated with cholestasis. As an example, jaundice may be the only presenting sign in patients with a urinary tract infection caused by <em>Escherichia</em> <em>coli</em> [<a href="#rid11">11,12</a>]. Bacterial infection also contributes to cholestasis in infants who receive parenteral nutrition [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/z/d/html/4959.html" rel="external">"Urinary tract infections in neonates"</a>.)</p><p class="headingAnchor" id="H1230190250"><span class="h1">GENETIC/METABOLIC DISORDERS</span></p><p class="headingAnchor" id="H11"><span class="h2">Alagille syndrome</span><span class="headingEndMark"> — </span>Alagille syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F118450&amp;token=87jLzclRwWxNoI%2BQq5Gg74V%2B2jCt4LsL%2BB%2BnqBwfLwgoe8ZNZ6oKZP7lpXiwtvuo&amp;TOPIC_ID=5945" target="_blank">MIM #118450</a>) is a genetic disorder associated with pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F601920&amp;token=87jLzclRwWxNoI%2BQq5Gg774xSAoGh1xfv48zrsTU3sqguhOZACU1cxJ%2FJwdr%2BZkS&amp;TOPIC_ID=5945" target="_blank"><i>JAG1</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F600275&amp;token=87jLzclRwWxNoI%2BQq5Gg71ccfWEtTEKgWzBy1w8isFuHtnp%2FqS2XEbs6LYvN1tod&amp;TOPIC_ID=5945" target="_blank"><i>NOTCH2</i></a> genes. The primary clinical manifestations are related to<em> </em>cholestatic liver disease (eg, pruritus and progressive hepatic fibrosis). Other common features include cardiac anomalies, butterfly vertebrae, posterior embryotoxon of the eye, renal abnormalities, and characteristic facial features  (<a class="graphic graphic_picture graphicRef53349" href="/z/d/graphic/53349.html" rel="external">picture 1</a> and <a class="graphic graphic_table graphicRef141282" href="/z/d/graphic/141282.html" rel="external">table 2</a>). The clinical manifestations and severity vary widely even among individuals within the same family.</p><p>The clinical features, diagnosis, and medical management of Alagille syndrome are discussed in detail in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/139432.html" rel="external">"Alagille syndrome"</a>.)</p><p class="headingAnchor" id="H3377024051"><span class="h2">Alpha-1 antitrypsin deficiency</span><span class="headingEndMark"> — </span>The presentation of some forms of AAT deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F613490&amp;token=87jLzclRwWxNoI%2BQq5Gg77eYIdiisusaTKryLwg0j%2BD6Ambh%2B%2FEEvja%2FM4QtDlED&amp;TOPIC_ID=5945" target="_blank">MIM #613490</a>) can include neonatal cholestasis. The frequency of AAT deficiency in infants with neonatal cholestasis ranges from 1 to 10 percent in different series [<a href="#rid15">15-17</a>]. AAT is an antiprotease and the natural inhibitor of the serine proteases released by activated neutrophils [<a href="#rid18">18</a>]. In patients with AAT liver disease, the abnormal protein accumulates within the endoplasmic reticulum, resulting in liver injury in a subset of patients by unclear mechanism [<a href="#rid19">19</a>].</p><p>The diagnosis of AAT deficiency is established by the protease inhibitor (PI) phenotyping system defined by isoelectric focusing of plasma [<a href="#rid19">19</a>]. The primary alleles associated with liver disease are PI*Z homozygosity or PI*SZ heterozygosity [<a href="#rid19">19</a>]. Of note, "null" genotypes, which result in no protein production, are not associated with liver disease, although they do cause severe lung disease that presents in adulthood (see  <a class="medical medical_review" href="/z/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency", section on 'AAT phenotypes'</a>). Affected individuals typically have decreased plasma AAT concentration because of impaired hepatic production. However, a normal AAT level does not exclude the diagnosis, because inflammation and tissue injury can markedly increase plasma AAT concentrations. (See  <a class="medical medical_review" href="/z/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency"</a>.)</p><p>PI*Z homozygotes most commonly present as neonatal hepatitis with cholestasis beginning in the first few months of life, and approximately 65 percent of these have severe liver disease [<a href="#rid20">20,21</a>]. Other clinical presentations among newborns include hepatomegaly with elevated aminotransferase levels (but without hyperbilirubinemia) and early evidence of moderate to severe liver disease with ascites and bleeding diathesis. Interestingly, AAT-associated liver disease that presents in the neonatal period often resolves spontaneously, and this presentation is not necessarily associated with a worse prognosis compared with later presentation during childhood [<a href="#rid20">20,22,23</a>]. The diagnosis and natural history of AAT deficiency are discussed in more detail in a separate topic review (see  <a class="medical medical_review" href="/z/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency", section on 'Hepatic disease'</a>). Liver transplantation has improved the prognosis of infants with severe liver disease [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H1977256048"><span class="h2">Arthrogryposis-renal dysfunction-cholestasis syndrome</span><span class="headingEndMark"> — </span>The cardinal features of arthrogryposis-renal dysfunction-cholestasis syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F208085&amp;token=87jLzclRwWxNoI%2BQq5Gg75THPyWIRSJRuKi0ko8Bhy5l7AmiXdeIysdzBq21Ygc1&amp;TOPIC_ID=5945" target="_blank">MIM #208085</a>) are arthrogryposis (multiple joint contractures), renal dysfunction, and cholestasis. The syndrome was previously thought to be rare but was found in 7 percent of infants presenting with cholestasis to a center in Korea [<a href="#rid25">25</a>]. The disorder is caused by mutations in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608552&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaElCFbwXT9A8Gvahnoywo3s&amp;TOPIC_ID=5945" target="_blank"><i>VPS33B</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F613401&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2BRTUW1mqyZYWvo2YvM7hmg%2BKt2N75dAno9%2BKmf4Fu6I&amp;TOPIC_ID=5945" target="_blank"><i>VIPAR</i></a><em> </em>genes and is an autosomal recessive trait; many patients are from consanguineous families [<a href="#rid26">26,27</a>].</p><p>In addition to the three cardinal features, affected infants generally have severe growth failure, ichthyosis, and central nervous system anomalies and may have cardiac defects, recurrent infections, and diarrhea. Unlike in many other cholestatic conditions, serum GGTP is usually normal. The infants also have a bleeding tendency, and patients undergoing liver biopsy often experience severe hemorrhage [<a href="#rid25">25,26</a>]. Thus, the diagnosis should be made by mutation analysis, and organ biopsy should be avoided. Although the severity of the phenotype varies, virtually all affected infants die during infancy [<a href="#rid25">25,28</a>].</p><p class="headingAnchor" id="H3853283582"><span class="h2">Cystic fibrosis</span><span class="headingEndMark"> — </span>Neonatal cholestasis is an uncommon presentation of CF, occurring in fewer than 5 percent of patients with CF [<a href="#rid29">29</a>]. In affected infants, jaundice and hepatomegaly slowly resolve. Infants with CF are more likely to present with meconium ileus or steatorrhea with failure to thrive. The CF transmembrane conductance regulator (CFTR) is located on the apical surface of the biliary epithelium, explaining some of the biliary tract disease seen in patients with CF [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">"Cystic fibrosis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/99126.html" rel="external">"Cystic fibrosis: Hepatobiliary disease"</a>.)</p><p class="headingAnchor" id="H2362614213"><span class="h2">Inborn errors of metabolism</span><span class="headingEndMark"> — </span>A variety of inborn errors of metabolism can present with neonatal cholestasis. These include disorders of carbohydrate (eg, galactosemia), amino acid (eg, tyrosinemia) and lipid metabolism, and bile acid synthetic and mitochondrial disorders. These disorders are outlined in the table  (<a class="graphic graphic_table graphicRef64995" href="/z/d/graphic/64995.html" rel="external">table 1A</a>), and selected disorders are highlighted below.</p><p class="headingAnchor" id="H1991045570"><span class="h3">Galactosemia</span><span class="headingEndMark"> — </span>Galactosemia (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F230400&amp;token=87jLzclRwWxNoI%2BQq5Gg767M2QW0iQE8dMlHTOO%2FBP%2Bgso91GcRsi1kmBxMf45iN&amp;TOPIC_ID=5945" target="_blank">MIM #230400</a>) is usually the result of galactose-1-phosphate uridyl transferase (GALT) deficiency. Affected infants present with mixed (conjugated and unconjugated) hyperbilirubinemia after the onset of galactose-containing feedings (eg, human or cow's milk); sepsis is also common at presentation. Associated features include vomiting, diarrhea, failure to thrive, renal tubular acidosis, cataracts, and coagulopathy.</p><p>The diagnosis is suggested by the presence of reducing substances in the urine and is confirmed by an assay of GALT activity in erythrocytes, leukocytes, or liver. Newborn screening for galactosemia is available in all states in the United States. Treatment requires elimination of dietary galactose and milk products, with substitution of soy formula (which does not contain any lactose). (See  <a class="medical medical_review" href="/z/d/html/2928.html" rel="external">"Galactosemia: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H4200715046"><span class="h3">Tyrosinemia</span><span class="headingEndMark"> — </span>Hereditary tyrosinemia type 1 (also known as hepatorenal tyrosinemia; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F276700&amp;token=87jLzclRwWxNoI%2BQq5Gg758IXybM4sM8wzM%2BmAi5Qs8wuJrvYexZS%2FaZ01nd10ix&amp;TOPIC_ID=5945" target="_blank">MIM #276700</a>) is caused by deficiency of fumarylacetoacetate hydrolase and presents in infancy. It is characterized by progressive liver disease, renal tubular acidosis, and neurologic impairment. Young infants present with cholestasis and coagulopathy, which is often disproportionate to the apparent degree of liver disease. Older infants and children may present with chronic liver disease (with or without cholestasis) and painful crises, mimicking porphyria.</p><p>Affected individuals have increased urinary excretion of succinylacetone and markedly elevated blood tyrosine concentration. Newborn screening for tyrosinemia type 1 is available in most states in the United States. The diagnosis and management of this disorder are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2935.html" rel="external">"Disorders of tyrosine metabolism", section on 'Hereditary tyrosinemia type 1'</a> and  <a class="medical medical_review" href="/z/d/html/4980.html" rel="external">"Overview of newborn screening"</a>.)</p><p class="headingAnchor" id="H2416515691"><span class="h3">Citrin deficiency</span><span class="headingEndMark"> — </span>Citrin deficiency (neonatal-onset type II citrullinemia; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F605814&amp;token=87jLzclRwWxNoI%2BQq5Gg7x1bT2FdUPeZTF07brQCXOZOd04jPMBuDvEgr%2BYuXVJ9&amp;TOPIC_ID=5945" target="_blank">MIM #605814</a>) is caused by a mutation of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F603859&amp;token=87jLzclRwWxNoI%2BQq5Gg76XNPK3lx6JuOZrMBsIrkRrquDGFi1JIEanKtror6w7d&amp;TOPIC_ID=5945" target="_blank"><i>SLC25A13</i></a> gene. Infants with citrin deficiency have transient intrahepatic cholestasis, diffuse fatty liver and parenchymal cellular infiltration associated with hepatic fibrosis, low birth weight, and growth retardation [<a href="#rid31">31</a>]. Citrin deficiency as a cause of neonatal intrahepatic cholestasis is more common in infants of Japanese or Chinese ancestry but has also been reported in other populations and is recognized to be pan-ethnic [<a href="#rid32">32,33</a>]. Liver function may be abnormal (eg, hypoproteinemia, decreased concentrations of coagulation factors, and/or hypoglycemia). Symptoms remit with fat-soluble vitamin supplementation and the use of lactose-free formula or formulas containing medium-chain triglycerides. Later in life, some of these patients may develop adult-onset citrullinemia type II (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F603471&amp;token=87jLzclRwWxNoI%2BQq5Gg76BRC7LM81sByDeNyxASsblqrU6fTe56ZAC3i%2BrUvdcW&amp;TOPIC_ID=5945" target="_blank">MIM #603471</a>), which is characterized by fatty liver, hyperammonemia, and neurologic symptoms [<a href="#rid34">34,35</a>]. (See  <a class="medical medical_review" href="/z/d/html/2929.html" rel="external">"Urea cycle disorders: Clinical features and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Disorders of lipid metabolism</span><span class="headingEndMark"> — </span>Disorders of lipid metabolism, including Wolman, Niemann-Pick type C, and Gaucher disease type 2, occasionally can present with cholestasis.</p><p>Wolman disease (also known as lysosomal acid lipase deficiency and cholesterol ester hydrolase deficiency; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F278000&amp;token=87jLzclRwWxNoI%2BQq5Gg74ZQlR%2BcogWr9WYcwQp%2F1Tz0wrkNoJJ4UIC8XdQTwhfc&amp;TOPIC_ID=5945" target="_blank">MIM #278000</a>) is an autosomal recessive disorder characterized by hepatosplenomegaly, hepatic fibrosis, adrenal calcification, adrenal insufficiency, malabsorption, and poor weight gain and is usually fatal in infancy [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/5813.html" rel="external">"Causes of primary adrenal insufficiency in children", section on 'Defects in cholesterol biochemistry'</a>.)</p><p>Niemann-Pick type C (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F257220&amp;token=87jLzclRwWxNoI%2BQq5Gg7z1I%2BbI2Bf9O%2FXtUbE5oJd%2BXwJGN6G%2Fak9DeFrWsmSqy&amp;TOPIC_ID=5945" target="_blank">MIM #257220</a>) and Gaucher disease type 2 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F230900&amp;token=87jLzclRwWxNoI%2BQq5Gg74Fq2O%2BvWuPOmKC%2FDeGq5aZuIFOkKhoXYvObxfkDnDzf&amp;TOPIC_ID=5945" target="_blank">MIM #230900</a>) are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6196.html" rel="external">"Overview of Niemann-Pick disease"</a> and  <a class="medical medical_review" href="/z/d/html/2918.html" rel="external">"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H19"><span class="h3">Disorders of bile acid metabolism</span><span class="headingEndMark"> — </span>Primary disorders of bile acid synthesis are caused by inherited defects in the enzymes that are necessary for synthesis of the two main bile acids (<a class="drug drug_pediatric" data-topicid="118809" href="/z/d/drug information/118809.html" rel="external">cholic acid</a> and chenodeoxycholic acid). Cholestasis results from an inadequate production of these bile acids, which are essential for bile flow, and increased production of aberrant bile acids, which are hepatotoxic.</p><p>Affected infants typically develop severe cholestatic jaundice from birth and progressive liver failure, sometimes with stools that are loose, fatty (steatorrhea), or pale-colored (acholic), and occasionally with pruritus [<a href="#rid38">38,39</a>]. Laboratory testing typically reveals conjugated hyperbilirubinemia and elevated aminotransferase activity (alanine transaminase [ALT] and aspartate transaminase [AST]), with paradoxically normal GGTP [<a href="#rid40">40</a>]. The clinical presentation of these disorders is variable. Milder forms may present in anicteric school-aged children as fat-soluble vitamin deficiency, pruritus, and/or neurologic disease with less prominent liver disease [<a href="#rid41">41</a>]. Types of single enzyme defects include [<a href="#rid42">42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Bile acid synthesis defect type 1 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607765&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoWRC6h8mWErMskiyrlDVeH&amp;TOPIC_ID=5945" target="_blank">MIM #607765</a>) – 3-beta-hydroxy-delta-5-C27-steroid oxidoreductase deficiency, due to a mutation in the <em>HSD3B7</em> gene [<a href="#rid39">39,43,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bile acid synthesis defect type 2 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F235555&amp;token=tEpDslnpc0F0kICl%2Fz7sFQJ0cbFqQ2rqnHzdjc4VeV00u%2F0b8oPYZnCTyX1ifO4Y&amp;TOPIC_ID=5945" target="_blank">MIM #235555</a>) – Delta[4]-3-oxosteroid 5-beta reductase deficiency, due to a mutation in the <em>AKR1D1</em> gene [<a href="#rid45">45,46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bile acid synthesis defect type 3 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613812&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5Bs2yRxTJaS5oAbuo38QMI&amp;TOPIC_ID=5945" target="_blank">MIM #613812</a>) – Oxysterol 7-alpha-hydroxylase deficiency, due to a mutation in the <em>CYP7B1</em> gene [<a href="#rid47">47</a>]. Mutations in this gene are also associated with a type of hereditary spastic paraplegia (SPG5). (See  <a class="medical medical_review" href="/z/d/html/14152.html" rel="external">"Hereditary spastic paraplegia", section on 'Autosomal recessive HSP'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bile acid synthesis defect type 4 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F214950&amp;token=tEpDslnpc0F0kICl%2Fz7sFZpszKvOtG3bo7mRUx02%2Blb5ePWS%2F2M7ybnrLfKfk036&amp;TOPIC_ID=5945" target="_blank">MIM #214950</a>) – Alpha-methylacyl-CoA racemase deficiency, due to a mutation the <em>AMACR</em> gene [<a href="#rid48">48,49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bile acid synthesis defect type 5 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F616278&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5%2FVq%2F3jIbp1st3Yzvrowkr&amp;TOPIC_ID=5945" target="_blank">MIM #616278</a>) – Due to a mutation in the <em>ABCD3</em> gene [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bile acid synthesis defect type 6 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F617308&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz53tTiXgkurPAGWmjYG6XoW&amp;TOPIC_ID=5945" target="_blank">MIM #617308</a>) – Due to a mutation in the <em>ACOX2</em> gene [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sterol 27-hydroxylase defect (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F213700&amp;token=tEpDslnpc0F0kICl%2Fz7sFZpszKvOtG3bo7mRUx02%2BlYI4f6FsVUfK5I%2FJ9OR146B&amp;TOPIC_ID=5945" target="_blank">MIM #213700</a>) – Also known as cerebrotendinous xanthomatosis. (See  <a class="medical medical_review" href="/z/d/html/1692.html" rel="external">"Cerebrotendinous xanthomatosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amidation defects:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Amino acid n-acyltransferase deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602938&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoktA4K%2FMwYQZ0Cr36ZDTi%2B&amp;TOPIC_ID=5945" target="_blank">MIM 602938</a>) – Due to a mutation in the <em>BAAT</em> gene</p><p class="bulletIndent2"><span class="glyph">•</span>Bile acid CoA ligase deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603314&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyof%2BgXU4caWw5ip%2FinQwlFT&amp;TOPIC_ID=5945" target="_blank">MIM 603314</a>) – Due to a mutation in the <em>SLC27A5</em> gene [<a href="#rid52">52</a>]</p><p></p><p>The diagnosis of a bile acid synthesis disorder is made using fast atom bombardment mass spectrometry and gas chromatography/mass spectrometry to demonstrate abnormal bile acids in the urine. Administration of bile acids (such as <a class="drug drug_pediatric" data-topicid="12872" href="/z/d/drug information/12872.html" rel="external">ursodeoxycholic acid</a>) will obscure bile acid analysis by this method and must be discontinued one week prior to urine collection for this assay. Genetic testing is also becoming more widely available [<a href="#rid53">53</a>].</p><p>Treatment with primary bile acids (cholic acid, not <a class="drug drug_pediatric" data-topicid="12872" href="/z/d/drug information/12872.html" rel="external">ursodeoxycholic acid</a> [ursodiol]) given orally normalizes liver function in some patients, depending on the specific defect and degree of illness at time of diagnosis [<a href="#rid42">42,54,55</a>]. <a class="drug drug_pediatric" data-topicid="118809" href="/z/d/drug information/118809.html" rel="external">Cholic acid</a> (Cholbam) was approved for this purpose by the US Food and Drug Administration in 2015 [<a href="#rid56">56</a>]. Efficacy has been demonstrated for bile acid synthesis defects types 1, 2, and 4 [<a href="#rid42">42,57</a>]. Amidation defects (amino acid n-acyltransferase deficiency or bile acid CoA ligase deficiency) respond to treatment with oral glycocholic acid, rather than cholic acid [<a href="#rid42">42,58</a>]. A detailed review of bile acid synthesis disorders is available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Frarediseases.org%2Frare-diseases%2Fbile-acid-synthesis-disorders%2F&amp;token=aWYUBJkjFZz6UiM%2FpuAkuMdsryCVjOBxZCEQrX5rJHb2TTnOFXXitoW7bmQZotsT96c7Ls6UJq6%2FN%2BIMlgU2868AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=5945" target="_blank">National Organization for Rare Disorders website</a> [<a href="#rid42">42</a>].</p><p>Other disorders are classified as secondary bile acid defects because they involve defects in the transport of bile acids. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Zellweger spectrum disorders (see  <a class="medical medical_review" href="/z/d/html/6147.html" rel="external">"Peroxisomal disorders", section on 'Zellweger spectrum disorders'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Smith-Lemli-Opitz syndrome (see  <a class="medical medical_review" href="/z/d/html/5813.html" rel="external">"Causes of primary adrenal insufficiency in children", section on 'Defects in cholesterol biochemistry'</a>)</p><p></p><p class="headingAnchor" id="H152563767"><span class="h3">Mitochondrial disorders</span><span class="headingEndMark"> — </span>A variety of mitochondrial disorders can present in the newborn period or early infancy with conjugated hyperbilirubinemia and hepatic dysfunction, with associated elevated serum aminotransferases, hypoglycemia, coagulopathy, and lactic acidosis [<a href="#rid59">59,60</a>]. Affected infants typically have lethargy and vomiting and often have neurologic signs such as weak cry, poor suck, hypotonia, apnea, and seizures. However, the type and degree of organ involvement varies among these disorders. There is also considerable variability in clinical phenotype within a single disorder because of differential content of mutant mitochondrial DNA (known as heteroplasmy). The main mitochondrial disorders that present with liver disease in infancy are outlined in the table  (<a class="graphic graphic_table graphicRef93730" href="/z/d/graphic/93730.html" rel="external">table 3</a>).</p><p class="bulletIndent1">Laboratory findings include hypoglycemia, acidosis, increased plasma lactate, elevated molar ratio of plasma lactate to pyruvate (greater than 20), elevation of the arterial ketone body ratio of beta-hydroxybutyrate to acetoacetate (greater than 2), and elevated creatinine kinase.</p><p></p><p>The diagnosis is confirmed by genotyping for the suspected gene (eg, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F601465&amp;token=87jLzclRwWxNoI%2BQq5Gg70MzGngkq6MHtWeWJgVI8H7lqoGlcLf%2BzKZjYV0H5Xot&amp;TOPIC_ID=5945" target="_blank"><i>DGUOK</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F174763&amp;token=87jLzclRwWxNoI%2BQq5Gg7z64KnGRlsB9frlUGFozYw%2B8c2qnEoWt%2Br%2FiHMlU39mz&amp;TOPIC_ID=5945" target="_blank"><i>POLG1</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F137960&amp;token=87jLzclRwWxNoI%2BQq5Gg79eOlrKbWUrwqGhfcUxKbtu0PWpBtwULTXwTwn%2FBrlig&amp;TOPIC_ID=5945" target="_blank"><i>MPV17</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F606075&amp;token=87jLzclRwWxNoI%2BQq5Gg74AOHKa%2BMVhD8sbWBKv04Z%2FcesQq%2BYUkRC8snAz1cThc&amp;TOPIC_ID=5945" target="_blank"><i>TWINKLE</i></a>, <em>or</em> <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F610230&amp;token=87jLzclRwWxNoI%2BQq5Gg7zDyP%2F%2BtRUPnIwssmI4boSJEMOt72hOylIiTmlC%2FHa1f&amp;TOPIC_ID=5945" target="_blank"><i>TRMU</i></a>); laboratories that perform these tests can be found at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=5945" target="_blank">Genetic Testing Registry website</a>. A number of panels are also available for parallel sequencing of multiple genes involved in mitochondrial disorders. Alternatively, direct measurement of respiratory chain enzyme activities can be performed in freshly frozen samples of affected tissues (liver, muscle, and, sometimes, skin fibroblasts or lymphocytes). Fatty acid oxidation defects should be considered in the differential diagnosis as they may present with a similar picture. (See  <a class="medical medical_review" href="/z/d/html/111790.html" rel="external">"Overview of fatty acid oxidation disorders"</a>.)</p><p>Liver transplantation is successful in some patients but may be contraindicated in those with neurologic or cardiac involvement [<a href="#rid59">59,61,62</a>]. (See  <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/83172.html" rel="external">"Acute liver failure in children: Management, complications, and outcomes", section on 'Liver transplant'</a>.)</p><p class="headingAnchor" id="H2087714703"><span class="h2">Progressive familial intrahepatic cholestasis</span><span class="headingEndMark"> — </span>Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous group of genetic disorders that lead to impaired bile flow. PFIC accounts for 10 to 15 percent of cases of neonatal cholestasis and 10 to 15 percent of liver transplants in children [<a href="#rid15">15,63</a>]. PFIC is classified into a number of different subtypes based on genetic etiology. Initially, the PFIC types were classified by numbers (PFIC types 1 through 5), but with the increased use of exome sequencing and other advanced genomic testing, the number of distinct genetic disorders has outpaced the classification system.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PFIC2</strong> – The most common type presenting in infancy is PFIC2 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F601847&amp;token=87jLzclRwWxNoI%2BQq5Gg7ycAV9ruN6NbhPuuFh5mtDZY%2BwPp9tyN4AXsMsh6zGhj&amp;TOPIC_ID=5945" target="_blank">MIM #601847</a>), which is caused by mutations in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F603201&amp;token=87jLzclRwWxNoI%2BQq5Gg78SxI6aWceYW9NzaRoHTHCYXtCbkpj0kgY9sj5PQ%2BGpN&amp;TOPIC_ID=5945" target="_blank"><i>ABCB11</i></a> gene, encoding the bile salt export pump [<a href="#rid64">64</a>]. Affected infants tend to have a rapid and severe course, with marked elevations in serum bile acids and intractable pruritus, and sometimes coagulopathy due to vitamin K malabsorption. Despite the severe cholestasis, concentrations of GGTP are paradoxically normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PFIC1 and PFIC4</strong> – Somewhat less common are PFIC1 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F211600&amp;token=87jLzclRwWxNoI%2BQq5Gg7ykYbHk2XjddMazuBiFmCK1qQOcczxYrja2GPzDNtdEH&amp;TOPIC_ID=5945" target="_blank">MIM #211600</a>; due to mutations in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F602397&amp;token=87jLzclRwWxNoI%2BQq5Gg7yJ1tUernCMWBOOxxKqm04%2BDV4ACPrtUbW32JS2QTffD&amp;TOPIC_ID=5945" target="_blank"><i>ATP8B1</i></a> gene, also known as Byler disease) and PFIC4 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F615878&amp;token=87jLzclRwWxNoI%2BQq5Gg73gcRgp6q%2FJI6XMUMMcd9COMZVPH%2FygONDs3vDCRD8lX&amp;TOPIC_ID=5945" target="_blank">MIM #615878</a>; due to mutations in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F607709&amp;token=87jLzclRwWxNoI%2BQq5Gg7ydaiFfuJ4g88gFPkhkWMLZlbBqQbJXrO8yem5lGpo33&amp;TOPIC_ID=5945" target="_blank"><i>TJP2</i></a> gene) [<a href="#rid65">65</a>]. These types may present any time in infancy and also tend to have severe cholestasis. As in PFIC2, the GGTP is normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PFIC3</strong> – The least common type to present as neonatal cholestasis is PFIC3, also known as MDR3 deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F602347&amp;token=87jLzclRwWxNoI%2BQq5Gg7xUgHBZNx6PC%2Fc88Bkbx3ePuoY%2F3GRRP9OWU8QSmq0ZH&amp;TOPIC_ID=5945" target="_blank">MIM #602347</a>), caused by mutations in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F171060&amp;token=87jLzclRwWxNoI%2BQq5Gg7y0%2BEGr5FsQZtygSRpUXLdg10B52GDGBmMXYR%2B5pYI9B&amp;TOPIC_ID=5945" target="_blank"><i>ABCB4</i></a> gene [<a href="#rid66">66</a>]. It is distinguished from the other types of PFIC by marked elevations of GGTP.</p><p></p><p>In addition to these traditionally recognized PFIC gene associations, several new genes have been identified as causing a PFIC phenotype. These include PFIC5 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F617049&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz43PlPBRUt0KGiF%2BUm7Nww0&amp;TOPIC_ID=5945" target="_blank">MIM #617049</a>), caused by mutations in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603826&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyq4seHfGcOcWGqeqjCpE7Gb&amp;TOPIC_ID=5945" target="_blank"><i>NR1H4</i></a> gene, which encodes the nuclear bile acid receptor FXR, identified in two families with neonatal cholestasis and a severe phenotype with rapid progression of liver disease [<a href="#rid67">67</a>]. Mutations in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606540&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypQFa9Ii7PUozieDWrRO5Fo&amp;TOPIC_ID=5945" target="_blank"><i>MYO5B</i></a> gene, the causative gene for microvillus inclusion disease, have also been reported in children with cholestasis and persistently low GGTP levels [<a href="#rid68">68,69</a>].</p><p>Genetics and management of these disorders are described separately. (See  <a class="medical medical_review" href="/z/d/html/3584.html" rel="external">"Inherited disorders associated with conjugated hyperbilirubinemia", section on 'Progressive familial intrahepatic cholestasis'</a>.)</p><p class="headingAnchor" id="H1121270319"><span class="h1">ALLOIMMUNE</span></p><p class="headingAnchor" id="H23"><span class="h2">Gestational alloimmune liver disease (neonatal hemochromatosis)</span><span class="headingEndMark"> — </span>Gestational alloimmune liver disease (GALD) is caused by transplacental passage of reactive maternal immunoglobulins [<a href="#rid70">70</a>]. It was previously known as neonatal hemochromatosis or neonatal iron storage disease, but those terms are misleading because the disorder is unrelated to hereditary hemochromatosis and iron deposition is a consequence, rather than a cause, of the liver injury.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – GALD is characterized by hepatic failure and hepatic and extrahepatic iron accumulation (hemosiderosis) during the neonatal period [<a href="#rid71">71</a>]. The onset is intrauterine, and newborns present with signs of severe liver failure, including coagulopathy, ascites, and hypoalbuminemia. Hyperbilirubinemia typically is both conjugated and unconjugated, although conjugated bilirubin levels may be only modestly elevated [<a href="#rid71">71</a>]. Hepatic cirrhosis in the neonate is common, underscoring the antenatal timing of the hepatic insult [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis may be suspected on the basis of the iron studies. Traditionally, demonstration of extrahepatic (or extra reticuloendothelial) iron was required for the diagnosis [<a href="#rid71">71,73,74</a>]. However, now that the alloimmune mechanism has been recognized, cases may be identified by the characteristic immunohistologic features of alloimmune disease that are present (specifically, the anti-human C5b-9 complex). Cases with these immunohistochemical findings and with either mild or severe disease and no iron overload have been reported [<a href="#rid75">75,76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – GALD is a result of maternal alloimmune injury (analogous to erythroblastosis fetalis) caused by transplacental passage of specific reactive maternal immunoglobulin G (IgG) [<a href="#rid77">77,78</a>]. The maternal alloantibody activates fetal complement cascade to produce a membrane attack complex and fetal liver injury. The characteristic feature of GALD is high levels of immunostaining for the anti-human C5b-9 complex (the terminal complement cascade) [<a href="#rid70">70</a>]. The target protein of the maternal immune response has not been identified.</p><p></p><p class="bulletIndent1">GALD can occur in the first pregnancy as well as subsequent pregnancies, suggesting that sensitization occurs during the pregnancy and not just at parturition (as is thought to be the case for most other gestational alloimmune diseases) [<a href="#rid79">79</a>]. The rate of recurrence of GALD in pregnancies subsequent to the index case is approximately 95 percent, including fetal loss as well as neonatal liver failure. The high recurrence rate is consistent with the mechanism of fetal alloimmune injury, rather than a genetic pattern of inheritance [<a href="#rid79">79,80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment for GALD may include antenatal and/or postnatal therapy, depending on when the disorder is identified:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antenatal therapy</strong> – For pregnant women with a previous pregnancy that resulted in an infant with GALD, antenatal therapy with high-dose intravenous immunoglobulin (<a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>) dramatically reduces the risk for recurrence of disease and also reduces the risk for fetal loss [<a href="#rid80">80-83</a>]. In a series of 188 pregnancies treated with IVIG (1 g/kg body weight/week beginning in week 14 or 18 of the pregnancy), 94 percent had no evidence of liver disease, compared with 30 percent for infants born of untreated pregnancies [<a href="#rid83">83</a>]. Among the 11 pregnancies with poor outcomes despite antenatal therapy, two ended with fetal loss and the nine live-born infants had severe GALD-related liver disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postnatal management</strong> – The combination of exchange transfusion and <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> is the current treatment of choice for neonates with GALD [<a href="#rid78">78,84-87</a>]. Liver transplantation remains an option for infants who do not respond to IVIG treatment.</p><p></p><p class="bulletIndent2">Treatment with high-dose <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>, usually given in combination with exchange transfusion, was described in a series of 16 infants with GALD [<a href="#rid87">87</a>]. The treated infants had a substantially increased rate of survival without liver transplantation (75 percent) as compared with historical controls (17 percent). A subsequent update suggests transplant-free survival up to 79 percent (35 of 44 infants treated with IVIG) [<a href="#rid88">88</a>]. Although this approach is based on limited clinical evidence, it is logical in view of the alloimmune mechanism of disease and the effectiveness of IVIG in gestational therapy [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1">Outcomes for infants who do not receive exchange transfusion or <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> are poor, with approximately 10 percent survival without liver transplantation [<a href="#rid80">80,84</a>]. Liver transplantation can be curative, but transplantation is difficult in this age group due to lack of appropriate donors and the increased risk of vascular and infectious complications. Thus, early referral is important. The outcomes of liver transplantation for GALD are fair but similar to the outcomes for other causes of acute liver failure in this age group [<a href="#rid84">84,89</a>].</p><p></p><p class="headingAnchor" id="H2470005886"><span class="h1">TOXIC</span></p><p class="headingAnchor" id="H27"><span class="h2">Intestinal failure (parenteral nutrition)-associated liver disease</span><span class="headingEndMark"> — </span>Intestinal failure-associated liver disease (IFALD) is defined as liver disease that arises as a consequence of the medical and surgical management strategies for intestinal failure, including short bowel syndrome. It is sometimes known as parenteral nutrition-associated liver disease because parenteral nutrition plays an important role in the pathogenesis of the disease. IFALD is the preferred term, in recognition that several other factors contribute to the disorder, including immaturity, intercurrent infections, and lack of enteral feedings.</p><p></p><p>IFALD is particularly common among premature infants with short bowel syndrome. The pathogenesis and management of IFALD are discussed in detail in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/5948.html" rel="external">"Intestinal failure-associated liver disease in infants"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">IDIOPATHIC NEONATAL HEPATITIS</span><span class="headingEndMark"> — </span>Idiopathic neonatal hepatitis is defined as prolonged conjugated hyperbilirubinemia without an obvious etiology after a complete evaluation has excluded identifiable infectious and metabolic/genetic causes. Characteristic findings on liver biopsy are multinucleated giant cells; variable inflammation with infiltration of lymphocytes, neutrophils, and eosinophils; and little or no bile duct proliferation [<a href="#rid90">90</a>]. However, these findings also are seen in other conditions, including alpha-1 antitrypsin (AAT) deficiency and progressive familial intrahepatic cholestasis (PFIC), among others.</p><p>With identification of specific disorders that had been previously included in this category, the reported incidence of idiopathic neonatal hepatitis has declined [<a href="#rid91">91</a>]. In a study of infants presenting with idiopathic cholestasis, outcomes were favorable, with a high rate of spontaneous resolution [<a href="#rid91">91</a>]. With continued improved diagnostic advances and identification of other specific causes, this entity, which is a diagnosis of exclusion, will become increasingly rare.</p><p class="headingAnchor" id="H2218309441"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116507.html" rel="external">"Society guideline links: Pediatric liver disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116513.html" rel="external">"Society guideline links: Neonatal jaundice"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116713.html" rel="external">"Society guideline links: Inherited liver disease"</a>.)</p><p class="headingAnchor" id="H3435604"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – The term "neonatal cholestasis" is often used to refer to cholestatic liver disease that is present at birth and/or develops within the first few months of life, rather than referring strictly to the neonatal period (the first 28 days of life). The hallmark of cholestasis is accumulation of components of bile in the bloodstream, due to diminished bile flow and/or excretion, and most frequently manifested as conjugated hyperbilirubinemia. (See <a class="local">'Definition and classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Neonatal cholestasis can be caused by obstruction, infection, genetic disorders (including metabolic defects), or alloimmune or toxic mechanisms  (<a class="graphic graphic_table graphicRef64995 graphicRef79511" href="/z/d/graphic/64995.html" rel="external">table 1A-B</a>). Key considerations are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biliary atresia</strong> – Biliary atresia is the most common cause of neonatal cholestasis. It must be differentiated from other causes promptly because early surgical intervention (ie, before two months of age) results in a better patient outcome. It is distinguished from other causes of neonatal cholestasis by a variety of tests, and the diagnosis is confirmed by intraoperative cholangiogram. (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infections</strong> – A variety of congenital and neonatally acquired infections can cause cholestasis, including those in the TORCH group of infections, and neonatal urinary tract infection. (See <a class="local">'Infectious causes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Genetic/metabolic disorders</strong> – Genetic causes of neonatal cholestasis include the following, as well as others detailed in the table  (<a class="graphic graphic_table graphicRef64995" href="/z/d/graphic/64995.html" rel="external">table 1A</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Alagille syndrome – This syndrome is characterized by chronic cholestasis with paucity of the interlobular bile ducts on liver biopsy. Other common features include cardiac anomalies, butterfly vertebrae, posterior embryotoxon of the eye, and characteristic facial features  (<a class="graphic graphic_picture graphicRef53349" href="/z/d/graphic/53349.html" rel="external">picture 1</a> and <a class="graphic graphic_table graphicRef141282" href="/z/d/graphic/141282.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/139432.html" rel="external">"Alagille syndrome"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cystic fibrosis (CF) – CF should be considered in infants with neonatal cholestasis, although it is an uncommon presentation of the disease. (See <a class="local">'Cystic fibrosis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Inborn errors of metabolism – Several inborn errors of metabolism present with cholestasis during the neonatal period, including galactosemia, tyrosinemia, citrin deficiency (neonatal-onset type II citrullinemia), and disorders of lipid and bile acid metabolism or mitochondrial function. Early identification is important because specific treatment is available for many of these disorders. (See <a class="local">'Inborn errors of metabolism'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Progressive familial intrahepatic cholestasis (PFIC) – This accounts for 10 to 15 percent of cases of neonatal cholestasis and 10 to 15 percent of liver transplants in children. (See <a class="local">'Progressive familial intrahepatic cholestasis'</a> above.)</p><p></p><p class="bulletIndent2">Gamma-glutamyl transpeptidase (GGTP) is elevated in the most common types of neonatal cholestasis, including biliary atresia. A few disorders are distinguished by relatively low or normal concentrations of GGTP, including the most common types of PFIC, bile acid synthetic disorders, and arthrogryposis-renal dysfunction-cholestasis syndrome. (See <a class="local">'Progressive familial intrahepatic cholestasis'</a> above and <a class="local">'Disorders of bile acid metabolism'</a> above and <a class="local">'Arthrogryposis-renal dysfunction-cholestasis syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alloimmune</strong> – Gestational alloimmune liver disease (GALD; previously known as neonatal hemochromatosis), mediated by transplacental passage of specific maternal antibodies, presents with neonatal liver failure. The combination of exchange transfusion and intravenous immunoglobulin (<a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>) is the treatment of choice for affected neonates. For pregnant women with a previous pregnancy that resulted in an infant with GALD, treatment with high-dose IVIG dramatically reduces the risk for recurrence of disease. (See <a class="local">'Gestational alloimmune liver disease (neonatal hemochromatosis)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Parenteral nutrition</strong> – Intestinal failure-associated liver disease (IFALD) is caused at least in part by prolonged exposure of a young infant to parenteral nutrition. The pathogenesis and management are discussed separately. (See <a class="local">'Intestinal failure (parenteral nutrition)-associated liver disease'</a> above and  <a class="medical medical_review" href="/z/d/html/5948.html" rel="external">"Intestinal failure-associated liver disease in infants"</a>.)</p><p></p><p class="headingAnchor" id="H1486395461"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert J Shulman, MD, Stephanie H Abrams, MD, MS, and Jessi Erlichman, MPH, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gottesman LE, Del Vecchio MT, Aronoff SC. Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects. BMC Pediatr 2015; 15:192.</a></li><li><a class="nounderline abstract_t">Harpavat S, Garcia-Prats JA, Anaya C, et al. Diagnostic Yield of Newborn Screening for Biliary Atresia Using Direct or Conjugated Bilirubin Measurements. JAMA 2020; 323:1141.</a></li><li><a class="nounderline abstract_t">Lien TH, Chang MH, Wu JF, et al. Effects of the infant stool color card screening program on 5-year outcome of biliary atresia in Taiwan. Hepatology 2011; 53:202.</a></li><li><a class="nounderline abstract_t">Singham J, Yoshida EM, Scudamore CH. Choledochal cysts: part 1 of 3: classification and pathogenesis. Can J Surg 2009; 52:434.</a></li><li><a class="nounderline abstract_t">Yamaguchi M. Congenital choledochal cyst. Analysis of 1,433 patients in the Japanese literature. Am J Surg 1980; 140:653.</a></li><li><a class="nounderline abstract_t">Todani T, Watanabe Y, Narusue M, et al. Congenital bile duct cysts: Classification, operative procedures, and review of thirty-seven cases including cancer arising from choledochal cyst. Am J Surg 1977; 134:263.</a></li><li><a class="nounderline abstract_t">Jiexiong F, Minju L, Hongfeng T, et al. Clinical and pathological characteristics of cystic lesions of extrahepatic bile duct in neonates. Acta Paediatr 2003; 92:1183.</a></li><li><a class="nounderline abstract_t">Kim WS, Kim IO, Yeon KM, et al. Choledochal cyst with or without biliary atresia in neonates and young infants: US differentiation. Radiology 1998; 209:465.</a></li><li><a class="nounderline abstract_t">Diao M, Li L, Cheng W. Timing of surgery for prenatally diagnosed asymptomatic choledochal cysts: a prospective randomized study. J Pediatr Surg 2012; 47:506.</a></li><li><a class="nounderline abstract_t">Caponcelli E, Knisely AS, Davenport M. Cystic biliary atresia: an etiologic and prognostic subgroup. J Pediatr Surg 2008; 43:1619.</a></li><li><a class="nounderline abstract_t">Seeler RA, Hahn K. Jaundice in urinary tract infection in infancy. Am J Dis Child 1969; 118:553.</a></li><li><a class="nounderline abstract_t">Rooney JC, Hill DJ, Danks DM. Jaundice associated with bacterial infection in the newborn. Am J Dis Child 1971; 122:39.</a></li><li><a class="nounderline abstract_t">Wolf A, Pohlandt F. Bacterial infection: the main cause of acute cholestasis in newborn infants receiving short-term parenteral nutrition. J Pediatr Gastroenterol Nutr 1989; 8:297.</a></li><li><a class="nounderline abstract_t">Sondheimer JM, Asturias E, Cadnapaphornchai M. Infection and cholestasis in neonates with intestinal resection and long-term parenteral nutrition. J Pediatr Gastroenterol Nutr 1998; 27:131.</a></li><li><a class="nounderline abstract_t">Hoerning A, Raub S, Dechêne A, et al. Diversity of disorders causing neonatal cholestasis - the experience of a tertiary pediatric center in Germany. Front Pediatr 2014; 2:65.</a></li><li><a class="nounderline abstract_t">Fischler B, Papadogiannakis N, Nemeth A. Aetiological factors in neonatal cholestasis. Acta Paediatr 2001; 90:88.</a></li><li><a class="nounderline abstract_t">Tan JJ, Cutiongco-dela Paz EM, Avila JM, Gregorio GV. Low incidence of alpha 1-antitrypsin deficiency among Filipinos with neonatal cholestatis. J Paediatr Child Health 2006; 42:694.</a></li><li><a class="nounderline abstract_t">Coakley RJ, Taggart C, O'Neill S, McElvaney NG. Alpha1-antitrypsin deficiency: biological answers to clinical questions. Am J Med Sci 2001; 321:33.</a></li><li><a class="nounderline abstract_t">Perlmutter DH. Alpha-1-antitrypsin deficiency. Semin Liver Dis 1998; 18:217.</a></li><li><a class="nounderline abstract_t">Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294:1316.</a></li><li><a class="nounderline abstract_t">Mostafavi B, Piitulainen E, Tanash HA. Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years. Int J Chron Obstruct Pulmon Dis 2019; 14:525.</a></li><li><a class="nounderline abstract_t">Teckman JH, Rosenthal P, Abel R, et al. Baseline Analysis of a Young α-1-Antitrypsin Deficiency Liver Disease Cohort Reveals Frequent Portal Hypertension. J Pediatr Gastroenterol Nutr 2015; 61:94.</a></li><li><a class="nounderline abstract_t">Teckman J, Rosenthal P, Hawthorne K, et al. Longitudinal Outcomes in Young Patients with Alpha-1-Antitrypsin Deficiency with Native Liver Reveal that Neonatal Cholestasis is a Poor Predictor of Future Portal Hypertension. J Pediatr 2020; 227:81.</a></li><li><a class="nounderline abstract_t">Francavilla R, Castellaneta SP, Hadzic N, et al. Prognosis of alpha-1-antitrypsin deficiency-related liver disease in the era of paediatric liver transplantation. J Hepatol 2000; 32:986.</a></li><li><a class="nounderline abstract_t">Jang JY, Kim KM, Kim GH, et al. Clinical characteristics and VPS33B mutations in patients with ARC syndrome. J Pediatr Gastroenterol Nutr 2009; 48:348.</a></li><li><a class="nounderline abstract_t">Gissen P, Tee L, Johnson CA, et al. Clinical and molecular genetic features of ARC syndrome. Hum Genet 2006; 120:396.</a></li><li><a class="nounderline abstract_t">Smith H, Galmes R, Gogolina E, et al. Associations among genotype, clinical phenotype, and intracellular localization of trafficking proteins in ARC syndrome. Hum Mutat 2012; 33:1656.</a></li><li><a class="nounderline abstract_t">Eastham KM, McKiernan PJ, Milford DV, et al. ARC syndrome: an expanding range of phenotypes. Arch Dis Child 2001; 85:415.</a></li><li><a class="nounderline abstract_t">Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr 1999; 28 Suppl 1:S1.</a></li><li><a class="nounderline abstract_t">Colombo C, Battezzati PM, Strazzabosco M, Podda M. Liver and biliary problems in cystic fibrosis. Semin Liver Dis 1998; 18:227.</a></li><li><a class="nounderline abstract_t">Chen ST, Su YN, Ni YH, et al. Diagnosis of neonatal intrahepatic cholestasis caused by citrin deficiency using high-resolution melting analysis and a clinical scoring system. J Pediatr 2012; 161:626.</a></li><li><a class="nounderline abstract_t">Yeh JN, Jeng YM, Chen HL, et al. Hepatic steatosis and neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) in Taiwanese infants. J Pediatr 2006; 148:642.</a></li><li><a class="nounderline abstract_t">Dimmock D, Maranda B, Dionisi-Vici C, et al. Citrin deficiency, a perplexing global disorder. Mol Genet Metab 2009; 96:44.</a></li><li><a class="nounderline abstract_t">Yasuda T, Yamaguchi N, Kobayashi K, et al. Identification of two novel mutations in the SLC25A13 gene and detection of seven mutations in 102 patients with adult-onset type II citrullinemia. Hum Genet 2000; 107:537.</a></li><li><a class="nounderline abstract_t">Lee BH, Jin HY, Kim GH, et al. Nonalcoholic fatty liver disease in 2 siblings with adult-onset type II citrullinemia. J Pediatr Gastroenterol Nutr 2010; 50:682.</a></li><li class="breakAll">Wolman disease. In: OMIM Online Menedlian Inheritance in Man. Johns Hopkins University. Available at: http://www.ncbi.nlm.nih.gov/omim (Accessed on April 21, 2012).</li><li><a class="nounderline abstract_t">Kyosen SO, Geocze S, Yamamoto MH, Martins AM. Endoscopic Findings in Lysosomal Acid Lipase Deficiency. J Pediatr Gastroenterol Nutr 2019; 68:e105.</a></li><li class="breakAll">Novak, DA, Suchy, et al. Disorders of the liver and biliary system relevant to clinical practice. In: Oski's Pediatrics: Principles and Practice, McMillan JA (Ed), Lippincott, Williams and Wilkins, Philadelphia 1999. p.1714.</li><li><a class="nounderline abstract_t">Subramaniam P, Clayton PT, Portmann BC, et al. Variable clinical spectrum of the most common inborn error of bile acid metabolism--3beta-hydroxy-Delta 5-C27-steroid dehydrogenase deficiency. J Pediatr Gastroenterol Nutr 2010; 50:61.</a></li><li><a class="nounderline abstract_t">Heubi JE, Setchell KD, Bove KE. Inborn errors of bile acid metabolism. Semin Liver Dis 2007; 27:282.</a></li><li><a class="nounderline abstract_t">Setchell KD, Heubi JE, Shah S, et al. Genetic defects in bile acid conjugation cause fat-soluble vitamin deficiency. Gastroenterology 2013; 144:945.</a></li><li class="breakAll">National Organization for Rare Disorders (NORD). Bile acid sythesis disorders. Available at: https://rarediseases.org/rare-diseases/bile-acid-synthesis-disorders/ (Accessed on June 10, 2020).</li><li><a class="nounderline abstract_t">Clayton PT, Leonard JV, Lawson AM, et al. Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids. J Clin Invest 1987; 79:1031.</a></li><li><a class="nounderline abstract_t">Schwarz M, Wright AC, Davis DL, et al. The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis. J Clin Invest 2000; 106:1175.</a></li><li><a class="nounderline abstract_t">Setchell KD, Suchy FJ, Welsh MB, et al. Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis. J Clin Invest 1988; 82:2148.</a></li><li><a class="nounderline abstract_t">Lemonde HA, Custard EJ, Bouquet J, et al. Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. Gut 2003; 52:1494.</a></li><li><a class="nounderline abstract_t">Setchell KD, Schwarz M, O'Connell NC, et al. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. J Clin Invest 1998; 102:1690.</a></li><li><a class="nounderline abstract_t">Setchell KD, Heubi JE, Bove KE, et al. Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy. Gastroenterology 2003; 124:217.</a></li><li><a class="nounderline abstract_t">Ferdinandusse S, Denis S, Clayton PT, et al. Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy. Nat Genet 2000; 24:188.</a></li><li><a class="nounderline abstract_t">Ferdinandusse S, Jimenez-Sanchez G, Koster J, et al. A novel bile acid biosynthesis defect due to a deficiency of peroxisomal ABCD3. Hum Mol Genet 2015; 24:361.</a></li><li><a class="nounderline abstract_t">Vilarinho S, Sari S, Mazzacuva F, et al. ACOX2 deficiency: A disorder of bile acid synthesis with transaminase elevation, liver fibrosis, ataxia, and cognitive impairment. Proc Natl Acad Sci U S A 2016; 113:11289.</a></li><li><a class="nounderline abstract_t">Chong CP, Mills PB, McClean P, et al. Bile acid-CoA ligase deficiency--a new inborn error of bile acid metabolism. J Inherit Metab Dis 2012; 35:521.</a></li><li><a class="nounderline abstract_t">Fawaz R, Baumann U, Ekong U, et al. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2017; 64:154.</a></li><li><a class="nounderline abstract_t">Hesham A-Kader H, Balistreri WF. Nontransplant alternatives for the treatment of patients with metabolic disease. Semin Liver Dis 1998; 18:255.</a></li><li><a class="nounderline abstract_t">Setchell KD, Heubi JE. Defects in bile acid biosynthesis--diagnosis and treatment. J Pediatr Gastroenterol Nutr 2006; 43 Suppl 1:S17.</a></li><li><a class="nounderline abstract_t">In brief: Cholic acid (Cholbam) for bile acid synthesis disorders. Med Lett Drugs Ther 2016; 58:56.</a></li><li><a class="nounderline abstract_t">Heubi JE, Setchell KDR. Open-label Phase 3 Continuation Study of Cholic Acid in Patients With Inborn Errors of Bile Acid Synthesis. J Pediatr Gastroenterol Nutr 2020; 70:423.</a></li><li><a class="nounderline abstract_t">Heubi JE, Setchell KD, Jha P, et al. Treatment of bile acid amidation defects with glycocholic acid. Hepatology 2015; 61:268.</a></li><li><a class="nounderline abstract_t">Molleston JP, Sokol RJ, Karnsakul W, et al. Evaluation of the child with suspected mitochondrial liver disease. J Pediatr Gastroenterol Nutr 2013; 57:269.</a></li><li><a class="nounderline abstract_t">Al-Hussaini A, Faqeih E, El-Hattab AW, et al. Clinical and molecular characteristics of mitochondrial DNA depletion syndrome associated with neonatal cholestasis and liver failure. J Pediatr 2014; 164:553.</a></li><li><a class="nounderline abstract_t">Dubern B, Broue P, Dubuisson C, et al. Orthotopic liver transplantation for mitochondrial respiratory chain disorders: a study of 5 children. Transplantation 2001; 71:633.</a></li><li><a class="nounderline abstract_t">Rake JP, van Spronsen FJ, Visser G, et al. End-stage liver disease as the only consequence of a mitochondrial respiratory chain deficiency: no contra-indication for liver transplantation. Eur J Pediatr 2000; 159:523.</a></li><li><a class="nounderline abstract_t">Srivastava A. Progressive familial intrahepatic cholestasis. J Clin Exp Hepatol 2014; 4:25.</a></li><li><a class="nounderline abstract_t">Knisely AS, Strautnieks SS, Meier Y, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006; 44:478.</a></li><li><a class="nounderline abstract_t">Sambrotta M, Strautnieks S, Papouli E, et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet 2014; 46:326.</a></li><li><a class="nounderline abstract_t">Degiorgio D, Colombo C, Seia M, et al. Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). Eur J Hum Genet 2007; 15:1230.</a></li><li><a class="nounderline abstract_t">Gomez-Ospina N, Potter CJ, Xiao R, et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun 2016; 7:10713.</a></li><li><a class="nounderline abstract_t">Gonzales E, Taylor SA, Davit-Spraul A, et al. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease. Hepatology 2017; 65:164.</a></li><li><a class="nounderline abstract_t">Cockar I, Foskett P, Strautnieks S, et al. Mutations in Myosin 5B in Children With Early-onset Cholestasis. J Pediatr Gastroenterol Nutr 2020; 71:184.</a></li><li><a class="nounderline abstract_t">Pan X, Kelly S, Melin-Aldana H, et al. Novel mechanism of fetal hepatocyte injury in congenital alloimmune hepatitis involves the terminal complement cascade. Hepatology 2010; 51:2061.</a></li><li><a class="nounderline abstract_t">Vohra P, Haller C, Emre S, et al. Neonatal hemochromatosis: the importance of early recognition of liver failure. J Pediatr 2000; 136:537.</a></li><li><a class="nounderline abstract_t">Ekong UD, Melin-Aldana H, Whitington PF. Regression of severe fibrotic liver disease in 2 children with neonatal hemochromatosis. J Pediatr Gastroenterol Nutr 2008; 46:329.</a></li><li><a class="nounderline abstract_t">Smith SR, Shneider BL, Magid M, et al. Minor salivary gland biopsy in neonatal hemochromatosis. Arch Otolaryngol Head Neck Surg 2004; 130:760.</a></li><li><a class="nounderline abstract_t">Hayes AM, Jaramillo D, Levy HL, Knisely AS. Neonatal hemochromatosis: diagnosis with MR imaging. AJR Am J Roentgenol 1992; 159:623.</a></li><li><a class="nounderline abstract_t">Debray FG, de Halleux V, Guidi O, et al. Neonatal liver cirrhosis without iron overload caused by gestational alloimmune liver disease. Pediatrics 2012; 129:e1076.</a></li><li><a class="nounderline abstract_t">Tsunoda T, Inui A, Kawamoto M, et al. Neonatal liver failure owing to gestational alloimmune liver disease without iron overload. Hepatol Res 2015; 45:601.</a></li><li><a class="nounderline abstract_t">Whitington PF, Malladi P. Neonatal hemochromatosis: is it an alloimmune disease? J Pediatr Gastroenterol Nutr 2005; 40:544.</a></li><li><a class="nounderline abstract_t">Whitington PF. Neonatal hemochromatosis: a congenital alloimmune hepatitis. Semin Liver Dis 2007; 27:243.</a></li><li><a class="nounderline abstract_t">Taylor SA, Kelly S, Alonso EM, Whitington PF. The Effects of Gestational Alloimmune Liver Disease on Fetal and Infant Morbidity and Mortality. J Pediatr 2018; 196:123.</a></li><li><a class="nounderline abstract_t">Whitington PF, Kelly S. Outcome of pregnancies at risk for neonatal hemochromatosis is improved by treatment with high-dose intravenous immunoglobulin. Pediatrics 2008; 121:e1615.</a></li><li><a class="nounderline abstract_t">Whitington PF, Hibbard JU. High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis. Lancet 2004; 364:1690.</a></li><li><a class="nounderline abstract_t">Baruteau J, Heissat S, Broué P, et al. Transient neonatal liver disease after maternal antenatal intravenous Ig infusions in gestational alloimmune liver disease associated with neonatal haemochromatosis. J Pediatr Gastroenterol Nutr 2014; 59:629.</a></li><li><a class="nounderline abstract_t">Whitington PF, Kelly S, Taylor SA, et al. Antenatal Treatment with Intravenous Immunoglobulin to Prevent Gestational Alloimmune Liver Disease: Comparative Effectiveness of 14-Week versus 18-Week Initiation. Fetal Diagn Ther 2018; 43:218.</a></li><li><a class="nounderline abstract_t">Heffron T, Pillen T, Welch D, et al. Medical and surgical treatment of neonatal hemochromatosis: single center experience. Pediatr Transplant 2007; 11:374.</a></li><li><a class="nounderline abstract_t">Timpani G, Foti F, Nicolò A, et al. Is exchange transfusion a possible treatment for neonatal hemochromatosis? J Hepatol 2007; 47:732.</a></li><li><a class="nounderline abstract_t">Sigurdsson L, Reyes J, Kocoshis SA, et al. Neonatal hemochromatosis: outcomes of pharmacologic and surgical therapies. J Pediatr Gastroenterol Nutr 1998; 26:85.</a></li><li><a class="nounderline abstract_t">Rand EB, Karpen SJ, Kelly S, et al. Treatment of neonatal hemochromatosis with exchange transfusion and intravenous immunoglobulin. J Pediatr 2009; 155:566.</a></li><li><a class="nounderline abstract_t">Whitington PF. Gestational alloimmune liver disease and neonatal hemochromatosis. Semin Liver Dis 2012; 32:325.</a></li><li><a class="nounderline abstract_t">Sheflin-Findling S, Annunziato RA, Chu J, et al. Liver transplantation for neonatal hemochromatosis: analysis of the UNOS database. Pediatr Transplant 2015; 19:164.</a></li><li><a class="nounderline abstract_t">CRAIG JM, LANDING BH. Form of hepatitis in neonatal period simulating biliary atresia. AMA Arch Pathol 1952; 54:321.</a></li><li><a class="nounderline abstract_t">Hertel PM, Hawthorne K, Kim S, et al. Presentation and Outcomes of Infants With Idiopathic Cholestasis: A Multicenter Prospective Study. J Pediatr Gastroenterol Nutr 2021; 73:478.</a></li></ol></div><div id="topicVersionRevision">Topic 5945 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26589959" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32207797" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnostic Yield of Newborn Screening for Biliary Atresia Using Direct or Conjugated Bilirubin Measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21140377" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effects of the infant stool color card screening program on 5-year outcome of biliary atresia in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19865581" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Choledochal cysts: part 1 of 3: classification and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6776832" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Congenital choledochal cyst. Analysis of 1,433 patients in the Japanese literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/889044" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Congenital bile duct cysts: Classification, operative procedures, and review of thirty-seven cases including cancer arising from choledochal cyst.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14632336" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical and pathological characteristics of cystic lesions of extrahepatic bile duct in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9807575" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Choledochal cyst with or without biliary atresia in neonates and young infants: US differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424346" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Timing of surgery for prenatally diagnosed asymptomatic choledochal cysts: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18778995" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cystic biliary atresia: an etiologic and prognostic subgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4897938" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Jaundice in urinary tract infection in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5567404" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Jaundice associated with bacterial infection in the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2496214" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bacterial infection: the main cause of acute cholestasis in newborn infants receiving short-term parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9702641" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Infection and cholestasis in neonates with intestinal resection and long-term parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25003101" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Diversity of disorders causing neonatal cholestasis - the experience of a tertiary pediatric center in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11227341" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Aetiological factors in neonatal cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17044896" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Low incidence of alpha 1-antitrypsin deficiency among Filipinos with neonatal cholestatis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11202478" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Alpha1-antitrypsin deficiency: biological answers to clinical questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9773422" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Alpha-1-antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1083485" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30880942" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651489" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Baseline Analysis of a Youngα-1-Antitrypsin Deficiency Liver Disease Cohort Reveals Frequent Portal Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32663593" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Longitudinal Outcomes in Young Patients with Alpha-1-Antitrypsin Deficiency with Native Liver Reveal that Neonatal Cholestasis is a Poor Predictor of Future Portal Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898319" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prognosis of alpha-1-antitrypsin deficiency-related liver disease in the era of paediatric liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19274792" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical characteristics and VPS33B mutations in patients with ARC syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16896922" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical and molecular genetic features of ARC syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22753090" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Associations among genotype, clinical phenotype, and intracellular localization of trafficking proteins in ARC syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11668108" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : ARC syndrome: an expanding range of phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9934970" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9773423" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Liver and biliary problems in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22575253" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Diagnosis of neonatal intrahepatic cholestasis caused by citrin deficiency using high-resolution melting analysis and a clinical scoring system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16737877" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hepatic steatosis and neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) in Taiwanese infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19036621" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Citrin deficiency, a perplexing global disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11153906" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Identification of two novel mutations in the SLC25A13 gene and detection of seven mutations in 102 patients with adult-onset type II citrullinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20400906" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nonalcoholic fatty liver disease in 2 siblings with adult-onset type II citrullinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20400906" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nonalcoholic fatty liver disease in 2 siblings with adult-onset type II citrullinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29762191" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Endoscopic Findings in Lysosomal Acid Lipase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29762191" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Endoscopic Findings in Lysosomal Acid Lipase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915491" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Variable clinical spectrum of the most common inborn error of bile acid metabolism--3beta-hydroxy-Delta 5-C27-steroid dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17682975" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Inborn errors of bile acid metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23415802" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Genetic defects in bile acid conjugation cause fat-soluble vitamin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23415802" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Genetic defects in bile acid conjugation cause fat-soluble vitamin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3470305" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11067870" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3198770" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970144" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9802883" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12512044" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655068" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25168382" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A novel bile acid biosynthesis defect due to a deficiency of peroxisomal ABCD3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27647924" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : ACOX2 deficiency: A disorder of bile acid synthesis with transaminase elevation, liver fibrosis, ataxia, and cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22089923" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Bile acid-CoA ligase deficiency--a new inborn error of bile acid metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27429428" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9773425" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Nontransplant alternatives for the treatment of patients with metabolic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16819396" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Defects in bile acid biosynthesis--diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27101212" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : In brief: Cholic acid (Cholbam) for bile acid synthesis disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31899729" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Open-label Phase 3 Continuation Study of Cholic Acid in Patients With Inborn Errors of Bile Acid Synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25163551" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of bile acid amidation defects with glycocholic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23783016" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Evaluation of the child with suspected mitochondrial liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24321534" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical and molecular characteristics of mitochondrial DNA depletion syndrome associated with neonatal cholestasis and liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11292292" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Orthotopic liver transplantation for mitochondrial respiratory chain disorders: a study of 5 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10923228" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : End-stage liver disease as the only consequence of a mitochondrial respiratory chain deficiency: no contra-indication for liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25755532" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Progressive familial intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871584" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24614073" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mutations in TJP2 cause progressive cholestatic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17726488" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26888176" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27532546" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32304554" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mutations in Myosin 5B in Children With Early-onset Cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20512994" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Novel mechanism of fetal hepatocyte injury in congenital alloimmune hepatitis involves the terminal complement cascade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10753255" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Neonatal hemochromatosis: the importance of early recognition of liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376253" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Regression of severe fibrotic liver disease in 2 children with neonatal hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210559" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Minor salivary gland biopsy in neonatal hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1503038" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Neonatal hemochromatosis: diagnosis with MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22392171" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Neonatal liver cirrhosis without iron overload caused by gestational alloimmune liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24976253" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Neonatal liver failure owing to gestational alloimmune liver disease without iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15861012" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Neonatal hemochromatosis: is it an alloimmune disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17682971" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Neonatal hemochromatosis: a congenital alloimmune hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29499991" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The Effects of Gestational Alloimmune Liver Disease on Fetal and Infant Morbidity and Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18474533" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Outcome of pregnancies at risk for neonatal hemochromatosis is improved by treatment with high-dose intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15530630" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25079484" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Transient neonatal liver disease after maternal antenatal intravenous Ig infusions in gestational alloimmune liver disease associated with neonatal haemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28787718" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Antenatal Treatment with Intravenous Immunoglobulin to Prevent Gestational Alloimmune Liver Disease: Comparative Effectiveness of 14-Week versus 18-Week Initiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17493216" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Medical and surgical treatment of neonatal hemochromatosis: single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17869371" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Is exchange transfusion a possible treatment for neonatal hemochromatosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9443126" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Neonatal hemochromatosis: outcomes of pharmacologic and surgical therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19560784" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Treatment of neonatal hemochromatosis with exchange transfusion and intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23397533" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Gestational alloimmune liver disease and neonatal hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557040" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Liver transplantation for neonatal hemochromatosis: analysis of the UNOS database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12984938" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Form of hepatitis in neonatal period simulating biliary atresia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34310436" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Presentation and Outcomes of Infants With Idiopathic Cholestasis: A Multicenter Prospective Study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
